Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
News Oct 31, 2015
Agilent Technologies Inc. has announced that the Australian Genome Research Facility Ltd—a nonprofit organization dedicated to enabling world-class genomics research throughout Australia—is now an Agilent Certified Service Provider for next-generation sequencing.
Agilent certifies select laboratories that leverage the company’s market-leading technologies to provide analysis services of the highest quality. The certification gives them access to Agilent technology and proven workflow solutions which, combined with their own expertise, will enable them to achieve reliable results.
With an Agilent Certified Service Provider, customers get reliable results from a validated lab, without the cost or technical challenges of implementing next-generation sequencing technology in their own lab.
“We are very pleased to announce our accreditation as an Agilent CSP,” said Sue Forrest, AGRF’s chief executive. “It is a natural extension of our accreditation from the National Association of Testing Authorities, our experience with the technology, and our commitment to quality.”
Established in 1997 under a government science infrastructure program, AGRF serves scientists in public and private enterprise through laboratories in five locations across Australia.
“Making Agilent’s innovative next-generation sequencing solutions easily accessible to researchers via a reputable service provider like the AGRF is going to help advance research outcomes in our region,” said Jeremy Dumsday, regional sales manager for Agilent’s Genomic Solutions.
Dumsday noted that Agilent’s Bioanalyzer, TapeStation, and SureSelect products are an integral part of AGRF’s service offerings.
“Agilent’s Genomics solutions can help researchers decode the link between genotype and phenotype faster, more cost-effectively and with confidence,” said Russell McInnes, director of sales for Agilent’s Diagnostics and Genomics Group in South Asia Pacific and Korea. “Clinical researchers across Asia Pacific can now leverage Agilent’s Genomics solutions for human and reproductive genetics and cancer genetics through the accredited next-generation sequencing services offered by AGRF.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.